Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 43 | 2020 | 1190 | 6.270 |
Why?
|
| Brain Ischemia | 32 | 2019 | 417 | 5.660 |
Why?
|
| Neuroprotective Agents | 10 | 2016 | 75 | 1.980 |
Why?
|
| Tissue Plasminogen Activator | 8 | 2016 | 126 | 1.960 |
Why?
|
| Cerebrovascular Circulation | 13 | 2012 | 178 | 1.660 |
Why?
|
| Clinical Trials as Topic | 15 | 2016 | 452 | 1.580 |
Why?
|
| Infarction, Middle Cerebral Artery | 7 | 2009 | 84 | 1.570 |
Why?
|
| Periodicals as Topic | 4 | 2017 | 174 | 1.390 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 11 | 2009 | 152 | 1.360 |
Why?
|
| Thrombectomy | 3 | 2019 | 227 | 1.210 |
Why?
|
| Fibrinolytic Agents | 5 | 2010 | 169 | 1.080 |
Why?
|
| Endovascular Procedures | 4 | 2019 | 644 | 1.080 |
Why?
|
| Editorial Policies | 2 | 2017 | 55 | 0.980 |
Why?
|
| Thrombolytic Therapy | 7 | 2016 | 190 | 0.970 |
Why?
|
| Reperfusion Injury | 4 | 2016 | 53 | 0.870 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2009 | 225 | 0.870 |
Why?
|
| Disease Models, Animal | 14 | 2013 | 2188 | 0.840 |
Why?
|
| Ischemic Attack, Transient | 4 | 2018 | 96 | 0.760 |
Why?
|
| Rats | 17 | 2013 | 1982 | 0.700 |
Why?
|
| Reperfusion | 5 | 2010 | 37 | 0.640 |
Why?
|
| Time Factors | 16 | 2019 | 3748 | 0.640 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2009 | 2156 | 0.610 |
Why?
|
| Drug Design | 3 | 2010 | 136 | 0.610 |
Why?
|
| Treatment Outcome | 13 | 2020 | 5606 | 0.560 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 195 | 0.550 |
Why?
|
| Anticoagulants | 5 | 2020 | 494 | 0.550 |
Why?
|
| Animals | 31 | 2016 | 20649 | 0.540 |
Why?
|
| Brain | 7 | 2007 | 1555 | 0.520 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2006 | 185 | 0.490 |
Why?
|
| Warfarin | 3 | 2020 | 110 | 0.480 |
Why?
|
| Health Planning Guidelines | 2 | 2007 | 32 | 0.470 |
Why?
|
| Humans | 43 | 2020 | 62931 | 0.470 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2008 | 622 | 0.460 |
Why?
|
| Ticlopidine | 2 | 2006 | 48 | 0.450 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 41 | 0.420 |
Why?
|
| Acute Disease | 8 | 2010 | 671 | 0.380 |
Why?
|
| Freezing | 1 | 2011 | 18 | 0.370 |
Why?
|
| Recovery of Function | 4 | 2019 | 285 | 0.360 |
Why?
|
| Embolism | 2 | 2008 | 41 | 0.350 |
Why?
|
| Thrombophilia | 1 | 2010 | 14 | 0.350 |
Why?
|
| Brain Injuries | 2 | 2013 | 139 | 0.340 |
Why?
|
| Aspirin | 2 | 2009 | 171 | 0.330 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 336 | 0.310 |
Why?
|
| Cerebral Infarction | 2 | 2007 | 83 | 0.310 |
Why?
|
| Research | 2 | 2009 | 192 | 0.310 |
Why?
|
| Intracranial Embolism | 1 | 2009 | 39 | 0.310 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2008 | 7 | 0.310 |
Why?
|
| Gadolinium | 1 | 2009 | 106 | 0.300 |
Why?
|
| Brain Infarction | 1 | 2008 | 21 | 0.300 |
Why?
|
| Male | 22 | 2019 | 29594 | 0.300 |
Why?
|
| Hyperoxia | 1 | 2008 | 17 | 0.300 |
Why?
|
| Behavior, Animal | 2 | 2007 | 230 | 0.300 |
Why?
|
| Biomedical Technology | 1 | 2007 | 6 | 0.270 |
Why?
|
| Contrast Media | 1 | 2009 | 422 | 0.270 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 40 | 0.260 |
Why?
|
| Rats, Wistar | 4 | 2013 | 185 | 0.260 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 837 | 0.260 |
Why?
|
| Middle Cerebral Artery | 1 | 2006 | 46 | 0.250 |
Why?
|
| Membrane Proteins | 1 | 2011 | 894 | 0.240 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2005 | 17 | 0.240 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 97 | 0.230 |
Why?
|
| Device Approval | 1 | 2005 | 13 | 0.230 |
Why?
|
| Telemedicine | 2 | 2009 | 319 | 0.230 |
Why?
|
| Diffusion | 5 | 2008 | 83 | 0.220 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 259 | 0.210 |
Why?
|
| Research Design | 2 | 2005 | 573 | 0.210 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 701 | 0.210 |
Why?
|
| Patient Selection | 3 | 2016 | 482 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 217 | 0.200 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 79 | 0.200 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 35 | 0.190 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2002 | 25 | 0.190 |
Why?
|
| Blood Pressure | 3 | 2010 | 509 | 0.180 |
Why?
|
| Neurons | 2 | 2011 | 921 | 0.180 |
Why?
|
| Disease Management | 1 | 2003 | 233 | 0.180 |
Why?
|
| Heparin | 1 | 2002 | 116 | 0.180 |
Why?
|
| Neuroimaging | 2 | 2013 | 154 | 0.180 |
Why?
|
| Astrocytes | 1 | 2002 | 119 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 5413 | 0.170 |
Why?
|
| Injections, Intravenous | 3 | 2006 | 156 | 0.170 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 463 | 0.170 |
Why?
|
| Risk Factors | 4 | 2019 | 5311 | 0.160 |
Why?
|
| China | 1 | 2019 | 165 | 0.160 |
Why?
|
| Rivaroxaban | 1 | 2018 | 19 | 0.150 |
Why?
|
| Dabigatran | 1 | 2018 | 20 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 1594 | 0.150 |
Why?
|
| Disability Evaluation | 1 | 2019 | 214 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2019 | 2051 | 0.140 |
Why?
|
| Regional Blood Flow | 2 | 2008 | 112 | 0.140 |
Why?
|
| Homes for the Aged | 1 | 2019 | 158 | 0.140 |
Why?
|
| Hemorrhage | 3 | 2019 | 267 | 0.140 |
Why?
|
| Aged | 6 | 2020 | 14278 | 0.130 |
Why?
|
| Protein C | 1 | 2016 | 26 | 0.130 |
Why?
|
| Secondary Prevention | 3 | 2018 | 163 | 0.130 |
Why?
|
| Nursing Homes | 2 | 2020 | 666 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1079 | 0.130 |
Why?
|
| Neurology | 1 | 2016 | 40 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 208 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2016 | 138 | 0.120 |
Why?
|
| Registries | 1 | 2019 | 879 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1638 | 0.120 |
Why?
|
| Middle Aged | 4 | 2019 | 17410 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 730 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 707 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6556 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 2 | 2005 | 93 | 0.100 |
Why?
|
| Diagnostic Imaging | 2 | 2008 | 263 | 0.100 |
Why?
|
| Language | 1 | 2014 | 147 | 0.100 |
Why?
|
| United States | 5 | 2020 | 7757 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 555 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2013 | 217 | 0.090 |
Why?
|
| Tetrazolium Salts | 2 | 2008 | 15 | 0.090 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2011 | 21 | 0.090 |
Why?
|
| Factor V Deficiency | 1 | 2010 | 1 | 0.090 |
Why?
|
| Protein S Deficiency | 1 | 2010 | 1 | 0.090 |
Why?
|
| Protein C Deficiency | 1 | 2010 | 2 | 0.090 |
Why?
|
| Antithrombin III Deficiency | 1 | 2010 | 2 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 258 | 0.090 |
Why?
|
| Medicare | 3 | 2020 | 610 | 0.090 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 13 | 0.090 |
Why?
|
| Cell Death | 1 | 2011 | 284 | 0.080 |
Why?
|
| Female | 5 | 2019 | 32587 | 0.080 |
Why?
|
| Cortical Spreading Depression | 1 | 2009 | 7 | 0.080 |
Why?
|
| Hospital Units | 1 | 2009 | 9 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 310 | 0.080 |
Why?
|
| Health Care Sector | 1 | 2009 | 20 | 0.080 |
Why?
|
| Magnetic Field Therapy | 1 | 2008 | 3 | 0.080 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2008 | 13 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2020 | 368 | 0.070 |
Why?
|
| Functional Laterality | 2 | 2006 | 138 | 0.070 |
Why?
|
| Species Specificity | 1 | 2009 | 336 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2007 | 666 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 174 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 156 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2010 | 483 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 297 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 577 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1114 | 0.070 |
Why?
|
| Injury Severity Score | 1 | 2007 | 111 | 0.070 |
Why?
|
| Equipment Design | 1 | 2008 | 348 | 0.070 |
Why?
|
| Virginia | 1 | 2007 | 25 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2156 | 0.070 |
Why?
|
| Radiography | 2 | 2006 | 539 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2006 | 13 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 728 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2009 | 554 | 0.060 |
Why?
|
| Brain Mapping | 1 | 2007 | 232 | 0.060 |
Why?
|
| Rats, Inbred WKY | 1 | 2005 | 11 | 0.060 |
Why?
|
| Body Temperature | 1 | 2005 | 45 | 0.060 |
Why?
|
| Drug Industry | 1 | 2005 | 39 | 0.060 |
Why?
|
| Legislation, Drug | 1 | 2005 | 17 | 0.060 |
Why?
|
| Equipment Safety | 1 | 2005 | 21 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 21 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2005 | 86 | 0.060 |
Why?
|
| Drug Approval | 1 | 2005 | 26 | 0.060 |
Why?
|
| Models, Animal | 1 | 2005 | 236 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 81 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 91 | 0.060 |
Why?
|
| Risk | 1 | 2005 | 377 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 496 | 0.050 |
Why?
|
| Aspirin, Dipyridamole Drug Combination | 1 | 2003 | 3 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2008 | 518 | 0.050 |
Why?
|
| Dipyridamole | 1 | 2003 | 17 | 0.050 |
Why?
|
| Heart Rate | 1 | 2005 | 321 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 455 | 0.050 |
Why?
|
| Software | 1 | 2007 | 386 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2005 | 122 | 0.050 |
Why?
|
| Oxygen | 1 | 2005 | 316 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2003 | 165 | 0.050 |
Why?
|
| Thrombosis | 1 | 2006 | 199 | 0.050 |
Why?
|
| Recurrence | 1 | 2005 | 638 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2547 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2005 | 767 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 934 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2003 | 143 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2003 | 199 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 371 | 0.050 |
Why?
|
| Adult | 2 | 2009 | 16664 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 250 | 0.050 |
Why?
|
| Disease Progression | 1 | 2005 | 1160 | 0.040 |
Why?
|
| Decision Making | 1 | 2004 | 401 | 0.040 |
Why?
|
| Water | 1 | 2002 | 308 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1540 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 2446 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2007 | 3263 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 42 | 0.040 |
Why?
|
| Algorithms | 1 | 2004 | 1001 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 66 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2018 | 73 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 284 | 0.040 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 83 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 208 | 0.040 |
Why?
|
| Urbanization | 1 | 2017 | 2 | 0.040 |
Why?
|
| Mice | 1 | 2011 | 10839 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2017 | 66 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 729 | 0.030 |
Why?
|
| Mechanical Thrombolysis | 1 | 2016 | 35 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 736 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 146 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2558 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 390 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 912 | 0.020 |
Why?
|
| Silicon | 1 | 2006 | 18 | 0.020 |
Why?
|
| Sutures | 1 | 2006 | 41 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 73 | 0.020 |
Why?
|
| Surface Properties | 1 | 2006 | 278 | 0.020 |
Why?
|